PATENT CLAIM ANALYSIS

Application Number: 15896309
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["424", "135100"]

Abstract:
The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.

Claim (Index 28):
The vector of  claim 27 , wherein the variable heavy chain further comprises at least one of the following residues:\n (i) Serine (S) at heavy chain amino acid position 12 (according to AHo numbering); (ii) Serine (S) or Threonine (T) at heavy chain amino acid position 103 (according to AHo numbering); and/or (iii) Serine (S) or Threonine (T) at heavy chain amino acid position 144 (according to AHo numbering).

Metadata:
- Claim Count in Document: 71.0
- Percentile: 88.0
- Lexical Diversity: 1.24444
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14740434', '15202982', '14072165', '15127976', '11836318']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7924877483191419
- 35 USC 102 Novelty (BERT): 0.6121324614634712
- Combined Prediction Score: 0.7744522196335749
- Mean Citation Score: 431.71069400000016
- Max Citation Score: 568.2968
- Similarity Product: 492.3573436749935

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test